Immunitybio (IBRX) Stock
Clinical biotech developing cancer and infectious disease therapies. Here's the price, business snapshot, and what's worth knowing about Immunitybio in July 2026.
ImmunityBio Inc. (IBRX) is a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases. It pursues a pipeline of biologics, engineered cell approaches and vaccine candidates intended to stimulate or modulate the immune system, using viral-vector and cytokine-based platforms. With a market capitalisation of about $2.40 billion, the stock reflects investor expectations about its clinical programmes and potential commercial opportunities. Key value drivers include trial read-outs, regulatory decisions, partnerships and financing. Like most clinical-stage biotechs, it carries higher volatility and binary outcomes — successful trials can materially increase value, while setbacks can lead to sharp declines. Investors should monitor cash runway, R&D spending and pipeline progress. This summary is educational and not personal financial advice; suitability depends on your circumstances and you should consult a qualified financial adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ImmunityBio's stock with a target price of $10.4, indicating growth potential.
Financial Health
ImmunityBio is performing well with strong profits, high revenue, and solid cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring IBRX
Biotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketAntiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Published: 16 November 2025
Explore BasketPharma Stocks: Could Pipeline Power Drive Growth?
Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published: 23 October 2025
Explore BasketOncology Stocks: Partnership Boom or Bubble Risk?
China's Innovent Biologics and Japan's Takeda Pharmaceutical have signed a multi-billion dollar deal to co-develop advanced cancer therapies. This landmark partnership signals a growing trend of international collaborations, creating potential investment opportunities among other biotech firms specializing in immuno-oncology and antibody-drug conjugates.
Published: 22 October 2025
Explore BasketPharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: 29 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical read-outs and regulatory milestones can move the share price significantly, though outcomes are binary and uncertain.
Platform Technology
Viral-vector and cytokine-based approaches aim to enhance immune response; technological promise requires clinical validation.
Funding & Partnerships
Collaborations and capital raises affect runway and commercial prospects, but financing can dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
